Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? – A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study

M. Kellner; S. Nowack; V. Wortmann; A. Yassouridis; K. Wiedemann

doi:10.1055/s-0035-1569371

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2016; 49(02): 79-81
DOI: 10.1055/s-0035-1569371

Letter to the Editor

Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? – A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study

M. Kellner

¹Department of Psychiatry and Psychotherapy, University Hospital Eppendorf, Hamburg, Germany

²Department of Psychosomatics and Psychotherapy, Medical Park Chiemseeblick, Bernau-Felden, Germany

,

S. Nowack

¹Department of Psychiatry and Psychotherapy, University Hospital Eppendorf, Hamburg, Germany

,

V. Wortmann

¹Department of Psychiatry and Psychotherapy, University Hospital Eppendorf, Hamburg, Germany

,

A. Yassouridis

³Max Planck Institute of Psychiatry, Munich, Germany

,

K. Wiedemann

¹Department of Psychiatry and Psychotherapy, University Hospital Eppendorf, Hamburg, Germany

› Author Affiliations

Abstract

Exposure therapy is an effective cognitive-behavioral treatment for patients with obsessive-compulsive disorder (OCD). However, a further amelioration of symptoms by additional drugs that enhance extinction learning is desirable. An interesting candidate is pregnenolone, which positively modulates NMDA and GABA_A receptors in preclinical studies and influences amygdala and prefrontal activity in humans. We present pilot data showing high acceptance and good tolerability of pregnenolone given 2 h before exposure sessions in OCD patients. As per our interim analyses, exposure treatment resulted in significantly improved main outcome parameters, but no effects of pregnenolone vs. placebo pretreatment were detectable thus far.

Key words

pregnenolone - obsessive-compulsive disorder (OCD) - exposure therapy

Full Text

References

References
1 McGuire JF, Lewin AB, Storch EA. Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Exp Rev Neurother 2014; 14: 893-910
2 Davis M, Myers KM, Chhatwal J et al. Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx 2006; 3: 82-96
3 Marx CE, Bradford DW, Hamer RM et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neurosci 2011; 191: 78-90
4 Sripada RK, Marx CE, King AP et al. Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biol Psychiatry 2013; 73: 1045-1053
5 Abramowitz JS. The psychological treatment of obsessive-compulsive disorder. Can J Psychiatry 2006; 51: 407-416
6 Rodrigues H, Figueira I, Lopes A et al. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLOS one 2014; 9: e93519
7 Chasson GS, Buhlmann U, Tolin DF et al. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with D-cycloserine. Beh Res Ther 2010; 48: 675-679
8 Lakatos A, Reinecker H. Cognitive Behavior Therapy in Obsessive-Compulsive Disorder. Göttingen: Hogrefe. 1999
9 Goodman W, Rasmussen S, Price L et al. Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Verhaltenstherapie 1991; 1: 226-233
10 Hautzinger M. The Beck Depression Inventory in clinical practice. Nervenarzt 1991; 62: 689-696
11 Rothbaum RO, Price M, Jovannovic T et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 2014; 171: 640-648
12 Rodebaugh TL, Levinson CA, Lenze EJ. A high-throughput clinical assay for testing drug facilitation of exposure therapy. Depress Anxiety 2013; 30: 631-637